Iron oxide magnetic particles
US-2024058449-A1 · Feb 22, 2024 · US
US2016367671A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016367671-A1 |
| Application number | US-201514745639-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jun 22, 2015 |
| Priority date | Jun 22, 2015 |
| Publication date | Dec 22, 2016 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
There is provided a nanoparticle composition comprising a central core portion including magnetic nanoparticles adapted to act as a heat source and a chemotherapeutic agent configured to treat cancer tissues in issue, a shell portion including a shell member encapsulating the core portion, antibodies configured to target cancer stem cells in issue and adhered to surface of said shell member. There is also provided a method comprising a step of exposing a target site in which the cancer cells reside to an energy source for effecting elevation of temperature of the magnetic nanoparticles, and release of the chemotherapeutic agent from the shell portion for destroying the cancer cells of the composition-cancer cell complex in the target site, wherein the energy source is an alternating magnetic field whereby extent of elevation of temperature and release of the chemotherapeutic agent is controllable by the alternating magnetic field.
Opening claim text (preview).
1 . A nanoparticle composition comprising a central core portion including magnetic nanoparticles adapted to act as a heat source and a chemotherapeutic agent configured to treat cancer tissues in issue, a shell portion including a shell member encapsulating said core portion, antibodies configured to target cancer stem cells in issue and adhered to surface of said shell member. 2 . A nanoparticle composition as claimed in claim 1 , furthering comprising fluorescent dyes for in vivo localization. 3 . A composition as claimed in claim 1 , wherein said shell member is made of silica or a silica based material. 4 . A composition as claimed in claim 1 , wherein diameter or width of said composition ranges from substantially 5 to 500 nanometers. 5 . A composition as claimed in claim 1 , wherein said shell member has a thickness from 10 to 100 nanometers. 6 . A composition as claimed in claim 1 , wherein said magnetic nanoparticles have a diameter or width from 1 to 50 nanometers. 7 . A composition as claimed in claim 1 , wherein said magnetic nanoparticles are magnetically responsive, and comprise or are super-paramagnetic nanoparticles. 8 . A composition as claimed in claim 1 , wherein said magnetic nanoparticles are configured to be responsive to alternating magnetic field. 9 . A composition as claimed in claim 1 , wherein said magnetic nanoparticles comprise Fe 3 O 4 particles. 10 . A composition as claimed in claim 1 , wherein said chemotherapeutic agent comprises or is a heat shock protein inhibitor. 11 . A composition as claimed in claim 1 , wherein said antibodies are coated on outwardly facing surface of said shell member. 12 . A composition as claimed in claim 1 , wherein said antibodies are specifically against surface molecules of cancer stem cells. 13 . A method of treatment of cancer by way of targeting cancer stem cells, comprising administering a nanoparticle composition as claimed in claim 1 . 14 . A method as claimed in claim 13 , comprising a step of forming a complex of the composition and the target cancer stem cells. 15 . A method as claimed in claim 13 , comprising a step of exposing a target site in which the cancer cells reside to an energy source for effecting elevation of temperature of the magnetic nanoparticles, and release of the chemotherapeutic agent from the shell portion for destroying the cancer cells of the composition-cancer cell complex in the target site, wherein the energy source is an alternating magnetic field whereby extent of elevation of temperature and release of the chemotherapeutic agent is controllable by the alternating magnetic field. 16 . A method as claimed in claim 15 , comprising a step of elevating temperature of the target site to 40° C. to 52° C. 17 . A method as claimed in claim 13 , comprising a step of administering said nanoparticle composition intravenously, or at a dose of 10 μg to 500 mg of said nanoparticle composition intravenously per kg of body weight. 18 . A method as claimed in claim 13 , comprising said administration of the nanoparticle composition once a week. 19 . Use of a composition as claimed in claim 1 for treatment of cancer.
Antineoplastic agents · CPC title
comprising antibodies · CPC title
Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds · CPC title
Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy · CPC title
Medicinal preparations obtained by treating materials with wave energy or particle radiation {; Therapies using these preparations} · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.